TLX — Telix Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual balance sheet for Telix Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	ARS	ARS	ARS	Interim Report	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	77.9	22	116	123	710
Net Total Accounts Receivable
Net Total Receivables	14.2	20.8	45.9	72.4	159
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	93.6	47.5	173	233	919
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	4.82	6.33	18.8	30.5	54.3
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	158	110	255	406	1,516
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	20	38	85.6	165	331
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	78.8	108	175	257	948
Common Stock
Retained Earnings (Accumulated Deficit)
Unrealized Gain / Loss
Other Equity
Total Equity	79	2.16	80	149	568
Total Liabilities & Shareholders' Equity	158	110	255	406	1,516
Total Common Shares Outstanding